Successful therapy with argatroban for superior mesenteric vein thrombosis in a patient with congenital antithrombin deficiency.

Abstract

A 38-year-old woman was admitted with superior mesenteric vein (SMV) thrombosis, which was refractory to anticoagulation therapy. The plasma antithrombin activity was decreased and hardly compensated by concentrated antithrombin preparation due to high consumption rate. However, successful anticoagulation was achieved by administration of direct thrombin inhibitor, argatroban. Family studies of antithrombin activity revealed that she had type I congenital antithrombin deficiency. A novel heterozygous mutation in the gene for antithrombin (single nucleotide T insertion at 7916 and 7917, Glu 272 to stop in exon 4) was identified. Argatroban administration would be effective in the treatment of congenital antithrombin deficiency with SMV thrombosis.

• Authors: Tsuyoshi Muta, Takashi Okamura, Masahiko Kawamoto, Hitoshi Ichimiya, Motoko Yamanaka, Yui Wada, Michiyo Urata, Yuzo Kayamori, Naotaka Hamasaki, Koji Kato, Testuya Eto, Hisashi Gondo, Tsunefumi Shibuya
• Journal: European journal of haematology (Eur J Haematol) Vol. 75 Issue 2 Pg. 167-70 (Aug 2005) ISSN: 0902-4441 [Print] England
• PMID: 16000134 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright Blackwell Munksgaard 2005.

Chemical References

• Pipecolic Acids
• Sulfonamides
• Arginine
• argatroban

Topics

• Adult
• Antithrombin III Deficiency (complications, congenital, genetics)
• Arginine (analogs & derivatives)
• DNA Mutational Analysis
• Female
• Frameshift Mutation
• Heterozygote
• Humans
• Mesenteric Vascular Occlusion (drug therapy)
• Mesenteric Veins
• Pipecolic Acids (administration & dosage)
• Salvage Therapy
• Sulfonamides
• Treatment Outcome
• Venous Thrombosis (drug therapy)